FDA Approves Cassipa Sublingual Film For Maintenance Treatment Of Opioid Dependence

- Sep 13, 2018 -

FDA approves Cassipa sublingual film for maintenance treatment of opioid dependence

  The U.S. Food and Drug Administration today approved Cassipa (buprenorphine and naloxone) sublingual film (applied under the tongue) for the maintenance treatment of opioid dependence. This action provides a new dosage strength (16 milligrams/4 milligrams) of buprenorphine and naloxone sublingual film, which is also approved in both brand name and generic versions and in various strengths.


Related News

Related Products

  • CAS:75885-58-4
  • 3-((2S,4S)-4-Mercaptopyrrolidine-2-carboxamido)benzoic Acid Hydrochloride
  • Succinic Acid
  • 4-nitrobenzyl 2-diazo-3-oxobutanoate
  • C6H8O4
  • Fomesafen 72178-02-0